Baxter International has announced it has entered into a definitive agreement to acquire Gambro AB for approximately $4 billion, according to a news release.
Gambro is a privately held dialysis product company based in Sweden. It is focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease.
"Baxter has a legacy of innovation in dialysis, including the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home. This acquisition further strengthens our global dialysis offerings by extending our portfolio in the hemodialysis segment," said Robert L. Parkinson Jr., chairman and CEO of Baxter, in the release. "This transaction will provide attractive returns and enhance Baxter's sales and earnings growth over the company's current long-range financial plan."
The closing of the transaction is expected to occur in the first half of 2013.
Baxter International is headquartered in Deerfield, Ill.
Related Articles on Company Acquisitions:
Volcano Corp. to Acquire Crux Biomedical
Merit Medical Systems Acquires Medigroup
Smith & Nephew to Acquire Healthpoint Biotherapeutics for $782M